Halozyme Therapeutic Expands Collaboration, License Deal With Argenx Over Development, Commercialization Of ENHANCE With Two Additional Targets

Halozyme Therapeutics, Inc. (Nasdaq: HALO) has expanded its collaboration and license agreement with argenx to include the development and commercialization of ENHANZE® for two additional exclusive targets. This strategic move enhances their partnership and broadens the scope of their therapeutic developments.